Effect of Rituximab on B Cell Phenotype and Serum B Cell-Activating Factor Levels in Patients With Thrombotic Thrombocytopenic Purpura

Clinical and Experimental Immunology - United Kingdom
doi 10.1111/cei.12472
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Clonal B-Cell Populations in Patients With Idiopathic Thrombocytopenic Purpura

Blood
BiochemistryImmunologyCell BiologyHematology
1990English

Rituximab-Induced Acute and Delayed Serum Sickness in Thrombotic Thrombocytopenic Purpura: The Role of Anti-Rituximab Antibodies

British Journal of Haematology
Hematology
2018English

High Serum B Cell Activating Factor Predicts Good Clinical Response to Rituximab in RA: Pilot Data

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2010English

Increased B�cell Activating Factor Is Associated With B�cell Class Switching in Patients With Tuberculous Pleural Effusion

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Thrombotic Thrombocytopenic Purpura

American Journal of Medicine
Medicine
1959English

Thrombotic Thrombocytopenic Purpura

Laboratory Medicine
BiochemistryClinical Biochemistry
1988English

TLR4 Promotes B Cell Maturation: Independence and Cooperation With B Lymphocyte-Activating Factor

Journal of Immunology
AllergyImmunology
2010English

Acquired Thrombotic Thrombocytopenic Purpura

2020English

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated With or Without Rituximab

Thrombosis and Haemostasis
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy